Administration Plans Steep Tariffs for Drugmakers Lacking U.S. Pricing Deals
U.S. officials are preparing to announce tariffs on pharmaceutical companies that have not struck deals to guarantee lower prices domestically, with a potential 100% tariff on imported branded and patented medicines. Some multinational drugmakers have negotiated exemptions by committing to pricing arrangements and U.S. investment, while others have…